Toronto Dominion Bank Immuno Gen, Inc. Transaction History

Toronto Dominion Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	BUY	$3.15 - $5.76 $611 - $1,117	194 New	194 $1,000
Q1 2022 May 09, 2022	SELL	$4.26 - $7.48 $754,961 - $1.33 Million	-177,221 Closed	0 $0
Q4 2021 Feb 04, 2022	BUY	$4.75 - $7.5 $835,444 - $1.32 Million	175,883 Added 13145.22%	177,221 $1.32 Million
Q3 2021 Nov 08, 2021	SELL	$5.02 - $6.59 $36,329 - $47,691	-7,237 Reduced 84.4%	1,338 $8,000
Q2 2021 Aug 13, 2021	BUY	$5.79 - $8.6 $49,649 - $73,745	8,575 New	8,575 $57,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

Stay updated on Toronto Dominion Bank with notifications on news.